Media stories about Stryker (NYSE:SYK) have trended somewhat positive on Saturday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Stryker earned a news impact score of 0.19 on Accern’s scale. Accern also gave news coverage about the medical technology company an impact score of 46.8025886863118 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Watermark Risk Management International Promotes Carla Moore to Senior Vice President (prweb.com)
- Stryker (SYK) Now Covered by Analysts at Raymond James Financial (americanbankingnews.com)
- Analysts Issue Forecasts for Stryker Co.’s Q1 2019 Earnings (SYK) (americanbankingnews.com)
- Stryker Spine Division’s Tritanium® C Anterior Cervical Cage Gains Momentum With Surgeons (markets.financialcontent.com)
- Why ConMed Is Expected to Report a Slight Rise in Its Net Profit Margin in 2018 (finance.yahoo.com)
Several research analysts have recently weighed in on SYK shares. SunTrust Banks reissued a “buy” rating and set a $161.00 price target on shares of Stryker in a research report on Friday, November 17th. Robert W. Baird raised shares of Stryker from a “neutral” rating to an “outperform” rating in a research report on Friday, November 24th. ValuEngine cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker in a research report on Thursday, December 7th. Finally, BMO Capital Markets raised shares of Stryker to a “market perform” rating and set a $163.00 target price on the stock in a research report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the stock. Stryker presently has a consensus rating of “Buy” and a consensus target price of $164.76.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.95 by $0.01. The company had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.78 earnings per share. equities analysts forecast that Stryker will post 7.12 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.12%. Stryker’s payout ratio is 70.15%.
In related news, VP Yin C. Becker sold 23,221 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $165.96, for a total transaction of $3,853,757.16. Following the sale, the vice president now directly owns 10,499 shares in the company, valued at $1,742,414.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $164.09, for a total transaction of $1,214,266.00. The disclosure for this sale can be found here. Insiders have sold 43,611 shares of company stock worth $7,178,719 over the last 90 days. Insiders own 7.40% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Stryker (SYK) Earns Media Sentiment Rating of 0.19” was first posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/17/stryker-syk-earning-somewhat-favorable-media-coverage-study-shows/2003603.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.